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ABSTRACT
Major depressive disorder (MDD) is a common psychiatric
disorder that often features impairments in cognitive function,
and these cognitive symptoms can be important determinants of
functional ability. Vortioxetine is a multimodal antidepressant
that may improve some aspects of cognitive function in patients
with MDD, including attention, processing speed, executive
function, and memory. However, the cause of these effects is
unclear, and there are several competing theories on the underlying mechanism, notably including regionally-selective downstream enhancement of glutamate neurotransmission and
increased acetylcholine (ACh) neurotransmission. The current work
sought to evaluate the ACh hypothesis by examining vortioxetine’s
ability to reverse scopolamine-induced impairments in rodent tests
of memory and attention. Additionally, vortioxetine’s effects on
hippocampal extracellular ACh levels were examined alongside studies of vortioxetine’s pharmacokinetic profile. We found

Introduction
Major depressive disorder (MDD) patients commonly experience impairments in cognitive function, including deficits in
cognitive domains such as attention, executive function, speed
of processing, and memory (McIntyre et al., 2013). These
impairments are clinically important from the perspective
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that acute vortioxetine reversed scopolamine-induced impairments in social and object recognition memory, but did not
alter scopolamine-induced impairments in attention. Acute
vortioxetine also induced a modest and short-lived increase in
hippocampal ACh levels. However, this short-term effect is at
variance with vortioxetine’s moderately long brain half life (5.1
hours). Interestingly, subchronic vortioxetine treatment failed to
reverse scopolamine-induced social recognition memory deficits and had no effects on basal hippocampal ACh levels. These
data suggest that vortioxetine has some effects on memory that
could be mediated through cholinergic neurotransmission, however these effects are modest and only seen under acute dosing
conditions. These limitations may argue against cholinergic mechanisms being the primary mediator of vortioxetine9s cognitive
effects, which are observed under chronic dosing conditions in
patients with MDD.

that they may predict poor response to treatment with
selective serotonin (5-HT) reuptake inhibitors (Dunkin et al.,
2000; Withall et al., 2009), tend to remain prominent after
recovery of mood symptoms (Kuny and Stassen, 1995;
Herrera-Guzman et al., 2009, 2010), and are associated with
poor functional recovery (Jaeger et al., 2006). Thus, it is
important to identify effective treatment strategies for MDDassociated cognitive dysfunction in order to achieve a functional recovery in MDD patients.
Vortioxetine is a multimodal antidepressant that is approved for the treatment of MDD. Evidence from clinical trials
suggests that vortioxetine ameliorates some aspects of MDDassociated cognitive impairment, for example, speed of processing, executive function, and memory. This is supported by
evidence from a number of preclinical experiments (du Jardin
et al., 2014; Jensen et al., 2014; Wallace et al., 2014; Li et al.,

ABBREVIATIONS: ACh, acetylcholine; aCSF, artificial cerebrospinal fluid; ANOVA, analysis of variance; CE, collision energy; D-ACh, deuterated
ACh; 5-HT, serotonin; IT, information trial; MDD, major depressive disorder; RT, retention trial; SERT, serotonin transporter; VSDT, visual signal
detection task.
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Vortioxetine on Scopolamine-Induced Cognitive Impairment

Materials and Methods
Animals
A total of 321 adult male rats was used, that is, 144 Wistar rats
(Charles River Laboratories, France) for the social recognition memory tests, 69 Sprague Dawley OFA rats (Charles River Laboratories,
Saint Germain sur l9Arbresle, France) for the object recognition
experiments, 16 Sprague Dawley rats (Harlan Laboratories, Frederick, MD) for the visual signal detection task (VSDT), and 92 Sprague
Dawley rats (Charles River Laboratories, Indianapolis, IN) for the
in vivo microdialysis, ex vivo receptor occupancy, and pharmacokinetic interaction and exposure time course studies. Additionally,
social recognition memory experiments used juvenile Wistar rats as
stimulus animals that were not otherwise subjected to any experimental manipulations. All rats were group-housed in plastic cages
under temperature- and humidity-controlled conditions, a 12-hour
light/dark cycle, and with ad libitum access to food and water, except
where noted below. All procedures were performed in a manner
consistent with local guidelines on ethical research in animals and
were approved by the relevant authority or animal care and use
committee prior to the start of experiments.

Drugs and Chemicals
Vortioxetine HBr was synthesized by H. Lundbeck A/S scopolamine HBr trihydrate, and paroxetine maleate was purchased from
Sigma-Aldrich. Donepezil HCl monohydrate was purchased from
either Sigma-Aldrich (St. Louis, MO) or Sequoia Research Products
(Pangbourne, United Kingdom). SB216641 HCl was purchased from
Tocris Biosciences (Minneapolis, MN). Vortioxetine was dissolved
in a 20% (w/v) aqueous solution of 2-hydroxypropyl-b-cyclodextrin
(Roquette America, Keokuk, IA) and injected s.c. at a volume of
2 mL/kg. Scopolamine and donepezil were dissolved in saline and
injected s.c. at a volume of 1 mL/kg. Paroxetine and SB216641 were
used in ex vivo autoradiography experiments and were dissolved in
dimethylsulfoxide (Sigma-Aldrich). Specific information on the magnitude and timing of doses is reported below for each experiment type.
All doses are expressed as the mass of the active base. Vortioxetine
doses (10 mg/kg, s.c. acute, and 1.8 g per kg/food subchronically) were
chosen to target the top of the clinically-relevant vortioxetine dose
range based on ex vivo rat SERT occupancy experiments (Leiser et al.,
2014). Doses of scopolamine and donepezil were chosen independently
for each behavioral task based on the results of pilot experiments. In
general, the doses used were the minimum required to induce a
reliable effect in each behavioral task.
[3H]Escitalopram (70 Ci/mmol; 1 mCi/mL) was synthesized at
Amersham (Piscataway, NJ), whereas the 5-HT1B receptor antagonist
[3H]GR125743 (76 Ci/mmol; 0.1 mCi/mL) was purchased from PerkinElmer (Boston, MA).

Behavioral Experiments
Social Recognition Memory Task. The social recognition test
was conducted as described by Lemaire et al. (1994) with minor
modifications. The test consists of three steps, as follows: an information trial (IT), a delay, and a retention trial (RT). During the IT,
an unfamiliar juvenile rat was introduced into the home cage of an
adult rat for 5 minutes, then removed for the duration of the delay, and
reintroduced to the adult rat for the RT. During the IT and RT, the
time the adult rat spent investigating the juvenile was recorded.
Investigations were defined as sniffing, grooming, or closely following
the juvenile rat.
Control experiments were conducted to determine whether the
pharmacological manipulations alter investigation behavior per se.
For that purpose, adult rats were injected with vehicle or vortioxetine
(10 mg/kg, 1 hour s.c.) and scopolamine (0.25 mg/kg, 30 minutes s.c.)
before an initial contact with an unfamiliar juvenile rat. The time
spent investigating the juvenile rat was recorded. The rats used in
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2015). Much of the recent research efforts from our laboratory
have been aimed at understanding the biologic mechanism by
which vortioxetine exerts these beneficial effects on cognitive
function. Vortioxetine is a 5-HT transporter protein (SERT)
inhibitor, a 5-HT1A receptor agonist, 5-HT1B receptor partial
agonist, and 5-HT1D, 5-HT3, and 5-HT7 receptor antagonist
(Sanchez et al., 2015). Interestingly, vortioxetine’s 5-HT
receptor activity may confer the ability to indirectly modulate signaling through several other neurotransmitter systems, including norepinephrine, dopamine (Pehrson et al.,
2013), acetylcholine (ACh) and histamine (Mørk et al., 2013),
g-aminobutyric acid (Pehrson and Sanchez, 2015; Dale et al.,
2016), and glutamate (Dale et al., 2014; Pehrson and Sanchez,
2014; Riga et al., 2016). Several of these neurotransmitter
systems have known relationships to cognitive function, and we
have hypothesized that vortioxetine’s cognitive effects may be
specifically related to indirect modulation of g-aminobutyric
acid and glutamate neurotransmission (Pehrson and Sanchez,
2014), ACh, or histamine neurotransmission (Mørk et al., 2013).
Although these ideas are not necessarily mutually exclusive, it
is important to empirically investigate the relationship between vortioxetine’s effects on these neurotransmitter systems
and cognition.
ACh neurotransmission has a well-documented relationship to cognitive function. Speaking generally, improvements
of cognitive function can be consistently observed after
cholinergic receptor activation, whereas impairments tend to
be observed after cholinergic receptor antagonism. For example, antagonism of muscarinic cholinergic receptors using
scopolamine consistently impairs cognitive functions in domains such as attention, learning, and memory in rodents and
humans (Collerton, 1986; Molchan et al., 1992), and genetic
models featuring deletions of muscarinic M2 receptors show
impairments in behavioral flexibility and working memory, as
well as reductions in hippocampal long-term potentiation, an
electrophysiological measure conceptually associated with
memory function (Seeger et al., 2004). Antagonism of nicotinic
a7 or a4b2 cholinergic receptors also impairs memory function
in rodents (Levin, 1992, 2002; Dobryakova et al., 2015).
Moreover, improvements in cognitive performance or related
electrophysiological measures have been observed after pharmacological activation of muscarinic or nicotinic receptor targets (Levin, 1992; Levin and Rezvani, 2002; Dennis et al., 2016).
Acetylcholinesterase inhibitors such as donepezil, which increase synaptic availability of ACh by reducing the rate of
catabolism, improve memory function not only in rodent models
(e.g., Zarrindast et al., 2002), but also induce small but significant improvements in memory function in humans, whether in
schizophrenic patients [see meta-analysis (Ribeiz et al., 2010)],
or in patients with Alzheimer’s disease [see meta-analysis
(Birks, 2006)]. Thus, it appears in general that activation of
cholinergic neurotransmission, whether by direct pharmacological action on receptors or by increased ACh availability,
may be a mechanism that can be leveraged to improve cognition
across several different clinical populations.
These data may suggest that vortioxetine’s indirect effects
on cholinergic neurotransmission could represent a relevant
mechanism for the observed improvements in cognitive function among MDD patients. Therefore, the purpose of the
present study is to empirically evaluate the relationship
between vortioxetine’s effects on ACh neurotransmission
and cognition in preclinical animal models.
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retracted after a response or 5 seconds (whichever occurred first). If
rats failed to make a response in 5 seconds, then it was counted as an
omission. Incorrect responses (i.e., blank lever during a signal trial or
signal lever during a blank trial) and trial omissions resulted in no
food pellet delivery and a 2-second timeout (all lights in test chamber
turned off). Rats were trained until a criterion of $70% choice accuracy
was obtained for three consecutive sessions.
Test sessions were identical to training sessions except that three
signal intensities were used (i.e., 0.4-, 0.6-, and 1.5-lux increase above
blank conditions, order randomized) and presignal interval delays
of 3, 6, and 12 seconds (order randomized) were used. Test sessions consisted of 90 blank trials and 90 signal trials (i.e., 30 low,
30 moderate, and 30 high signal intensity trials). Once the training
criterion was met, test sessions occurred every third day. Animals
received at least one training session immediately preceding a test
session. Test sessions were conducted no more than twice per week
(typically Tuesdays and Fridays) and were separated by at least
72 hours. On test days, animals were injected with vehicle or
vortioxetine (10 mg/kg, s.c.) 1 hour, followed by scopolamine (0.1 or
0.25 mg/kg, s.c.) 30 minutes prior to test session start. The order of
drug combinations was determined by a randomized Latin-square
design. The initial scopolamine 0.25 mg/kg dose was chosen because
pilot experiments had demonstrated reliable impairment in VSDT
performance at this dose. The 0.1 mg/kg dose was included to assess
the extent to which vortioxetine’s effects on scopolamine-induced
VSDT performance depended on scopolamine dose.

Drug Exposure Studies
To assess a possible pharmacokinetic interaction between vortioxetine
and scopolamine, a separate set of rats was treated with vehicle or
vortioxetine (10 mg/kg, s.c.) 1 hour and scopolamine (0.1 mg/kg, s.c.) or
vehicle 30 minutes before sampling of plasma and brains. In addition, a
separate set of experiments was made to determine the relationship
between pretreatment time and plasma and brain concentration of
10 mg/kg vortioxetine, s.c. Toward this end, blood and brains were
collected at 1, 2, 4, 8, 12, and 16 hours after dosing. Rats were
anesthetized using CO2 and decapitated using a sharpened guillotine.
Blood was collected into vacutainers containing EDTA and gently
mixed for 30 seconds before placing on ice. Later, blood was centrifuged
at 3000 rpm for 15 minutes at 4°C. The plasma layer was collected and
frozen at 220°C until use. Brains were quickly dissected, flash frozen
on powdered dry ice, and stored at 20°C until analysis.
Frozen brains were weighed and homogenized in 3 (weight/
volume) brain homogenization buffer (50% water, 30% 2-propanol,
and 20% dimethylsulfoxide). A 150 mL internal standard (Lundbeck
compound AA34745) solution was added to 50 mL homogenized brain
sample, which was then vortexed and centrifuged. The supernatant
was collected for analysis of vortioxetine or scopolamine exposure. For
plasma samples, the internal standard solution was added to the
sample, as described above, before thorough mixing. In addition,
standard curves for vortioxetine and scopolamine (0–4000 ng/ml in
brain or 0–1000 ng/mL for plasma) were generated. The samples were
injected directly into an Aria TLX2 coupled with a TSQ Quantum
Ultra (both systems Thermo Electron, San Jose, CA). A Gemini
column (Kinetex, 2.6 mm C18, 50  2.1 mm; Phenomenex, Torrance,
CA) was used for analytical separation. A typical 3-minute gradient
with the following mobile phases was used: 0.1% formic acid in water
(solvent A) and 0.01% formic acid in acetonitrile (solvent B). The mass
spectrometer was equipped with a heated electrospray ionization
probe, and the source conditions were as follows: vaporizer temperature 450°C, spray voltage 3000, sheath gas at 40°C, ion sweep gas and
aux gas at 20°C, and capillary temperature at 300°C. Spectra were
acquired in positive selected reaction monitoring mode with the
parent masses of the following: vortioxetine 299.16 (m/z) and daughter
ion (1) 109 (m/z) at 37 collision energy (CE), daughter ion (2) 150 (m/z)
at 27 CE both at tube lens of 120; scopolamine 304.36 (m/z) and
daughter ion (1) 138 (m/z) at 20 CE and daughter ion (2) 103 (m/z) at
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these preliminary experiments were evenly distributed throughout
the experimental groups and used in the main social recognition
memory experiments after a 5-day washout.
In the study of acute vortioxetine, adult rats were randomly injected
with vehicle or vortioxetine (0.1, 1, 3, or 10 mg/kg, 1 hour s.c.) and
vehicle or scopolamine (0.25 mg/kg, 30 minutes s.c.) prior to the IT.
The delay lasted 30 minutes.
In the study of subchronic vortioxetine, adult rats were fed ad
libitum for 14–15 days with either a vehicle food (Purina 5001, Nestlé,
St. Louis, MO) or food infused with 1.8 g vortioxetine per kg food. On
the test day, rats received vehicle or scopolamine (0.25 mg/kg, s.c.),
and testing was performed, as described above.
Object Recognition Memory Task. The object recognition task
was performed in a Plexiglas Y-maze apparatus (45  15  33 cm)
placed in a room illuminated only by a halogen lamp orientated toward
the ceiling, which produced a uniform dim light in the maze of
approximately 60 lux (Bartolini et al., 1996; Bertaina-Anglade et al.,
2011). The objects were different in shape, color, and texture. In
addition, the objects were made of glass (white) and metal (gray),
about 14 cm high, and were too heavy to be moved by the rats. Each
pair of objects was validated in previous experiments to ensure the
absence of spontaneous preference for one of the pair. In each
experiment, the role (familiar versus novel object) as well as the
relative position of the two objects were counterbalanced and randomly permuted. Rats were placed in the experimental room for at
least 30 minutes prior to testing.
The experiment consisted of four sessions. On days 1 and 2, rats
received habituation sessions to the area and test room environment,
in which animals were allowed to freely explore the apparatus for
10 minutes per day. On the third day, rats were submitted to two
exploration trials with a 1-hour intertrial interval. During the IT (day
3, trial 1), animals were placed in the Y-maze containing two identical
objects and were given 5 minutes to explore the objects before being
returned to the home cage for the intertrial interval. Exploration was
defined as the animal having its head close to the object while looking
at, sniffing, or touching the object. Any rat not exploring the objects for
at least 15 seconds during the IT was excluded from the experiments.
In the RT (day 3, trial 2), animals were exposed to an identical copy of
one of the objects previously seen during the first trial and a novel
object. The RT lasted 5 minutes. The floor and walls of the Y-maze, as
well as the objects, were washed with 10% ethanol and dried
thoroughly after each trial. On day 3, rats were injected with vehicle,
vortioxetine (3.9 or 7.9 mg/kg, s.c.), or donepezil (0.4 or 1.3 mg/kg, s.c.)
1 hour and with vehicle or scopolamine (3.47 mg/kg, s.c.) 55 minutes
before the start of the IT.
Visual Signal Detection Task. The VSDT was conducted in four
identical operant chambers enclosed within sound-attenuating cubicles (Med-Associates, Fairfax, VT). Each chamber was equipped with
a signal light mounted above a food cup (centered on the front panel), a
house light, two retractable levers (on either side of the food cup), and a
fan to provide ventilation and white noise. The visual signal consisted
of an increased illumination intensity lasting for 500 ms.
The rats were trained and tested according to procedures adapted
from previously published experiments (Hillhouse and Prus, 2013;
Freitas et al., 2015; Hillhouse et al., 2015). Briefly, each trial started
with the house light and signal light on (background illumination of
0.9 lux). During training, a trial started with a consistent presignal
interval of 4 seconds, which is the attention portion of the trial. After
the presignal interval, rats experienced either a blank or signal trial
for 500 ms. Under blank trial conditions, there was no change in the
signal light illumination, whereas under signal trial conditions there
was a 1.5-lux increase in illumination intensity of the signal light to
2.4 lux for 500 ms. Next, a postsignal interval of 1 second preceded the
left and right levers extending into the chamber. If a rat pressed the
signal lever (randomly assigned as either the right or left lever) during
a signal trial, it was recorded as a hit and the rat received a food pellet.
If a rat pressed the blank lever during a blank trial, it was recorded
as a correct rejection and the rat received a food pellet. Levers were
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25 CE, both at tube lens of 115; internal standard 552.32 (m/z) and
daughter ion 203 (m/z) at 50 CE at tube lens of 120.

In Vivo Microdialysis Experiments

chromatography/mass spectrometry/mass spectrometry system. Column and tubing prior to column were maintained at 30°C. The mobile
phase consisted of an aqueous component (A: 100 mM ammonium
acetate in milliQ water) and an organic component (B: 100% acetonitrile). Isocratic elution of ACh (retention time 1.77 minutes) using 100%
A followed by a wash of the column using a fast ramp to 100% B and then
a re-equilibration of the column back to 100% A permitted separation of
the two analytes with a total run time of 5 minutes. Detection of the
analytes was performed by monitoring unique fragments formed from
parent ions of ACh [parent (146.05 Da) to fragment (86.3 Da)]. To correct
for sample and instrument variability, a D-ACh was incorporated into
the samples to act as an internal standard [parent (149.95 Da) to
fragment (90.15 Da)]. Utilizing this technique, a lower limit of detection
of 5 pg/mL was achieved.

Ex Vivo Target Occupancy Experiments
Ex vivo occupancy at the SERT and the 5-HT1B receptor was
determined after acute (10 mg/kg, s.c., 1 hour) and subchronic (1.8 g/kg
food for 15 days) vortioxetine. Rats were anesthetized with CO2 and
decapitated, and brains were dissected, frozen, and stored, as described above. Ex vivo occupancy experiments were performed, as
described previously (du Jardin et al., 2014; Wallace et al., 2014).
Briefly, frozen brain tissue was sectioned coronally at 20-mm thickness using a cryostat (MicroM, Waldorf, Germany) beginning at
∼1.5–1.2 mm anterior to Bregma (Paxinos, 1998). Slices were thaw
mounted on glass microscope slides and stored at 220°C after being
thoroughly dried. On the day of autoradiography experiments, plastic boxes containing slides were defrosted at room temperature for
at least 30 minutes under a constant airflow. Following a brief
preincubation at 4°C (5-HT1B receptor occupancy only), slides were
incubated for 1 h in an assay buffer containing 50 mM Tris HCl,
150 mM NaCl, and 5 mM KCl (pH 7.4) and 4.5 nM [3H]escitalopram
(SERT occupancy) or 170 mM Tris HCl, 4mM CaCl2, and 0.1% (w/v)
L-ascorbic acid and 1 nM [3H]GR125743 (5-HT1B receptor occupancy).
Nonspecific binding was determined on a separate slide by including with the radioligand a high concentration of a nonradioactive
competitor selective for the target in question, that is, 1 mM paroxetine
or 1 mM SB216641 for SERT and 5-HT1B receptor occupancy, respectively. After incubation, slides were washed twice in cold assay
buffer and briefly dipped in cold distilled water. Slides were air dried
under a fan for 30 minutes before being transferred to a vacuum
desiccator for at least 1 hour. Finally, an image of the slides was taken
using a b-imager (Biospace Laboratory, Nesles-la-Vallée, France) for
16 hours.

Statistics
All data are presented as mean 6 S.E.M. The criterion for statistical
significance was set at a 5 0.05, unless noted otherwise. Statistical
analyses were conducted using either GraphPad Prism 6.0 for
windows (GraphPad Software, La Jolla, CA), or MATLAB (Mathworks, Natick, MA).
Social Recognition Memory Task. For assessment of drug
effects on social exploration, the dependent measure was the time(s)
spent investigating a juvenile stimulus animal during an initial
exposure, and data were analyzed using an independent samples
t test. Within the memory experiments, the dependent measure was a
recognition index, defined as IT/(IT 1 RT)  100, where IT is defined
as the investigation time during the information trial, and RT is the
investigation time during the retention trial. Outliers were identified using Pierce’s criterion (Ross, 2003) and removed. The data
were subsequently analyzed by a one-way analysis of variance
(ANOVA), followed where appropriate by Fisher’s protected t post
hoc tests.
Object Recognition Task. Data were collected as time(s) spent
actively exploring the familiar (F) or novel (N) object during RT.
Recognition memory data are presented as a recognition index,
defined as follows: [(N 2 F)/(N 1 F)]  100. Animals with low level
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Anesthetized (isoflurane, 2%, 800 mL/min O2) rats were placed in
a stereotaxic frame (Kopf Instruments, Tujunga, California) and
implanted with CMA12 guide cannulas (CMA Microdialysis, Kista,
Sweden) in the ventral hippocampus (coordinates: anteroposterior
axis 5 25.3 mm relative to bregma; mediolateral axis 5 24.8 mm
relative to midline; dorsoventral axis 5 28.0 mm relative to dura)
(Paxinos, 1998). Skull screws were implanted, and a head cap was
constructed using dental cement. Lidocaine was used for local
anesthesia, and carprophen (5 mg/kg s.c.) was used as a pre- and
postoperative analgesic. After surgery, animals were singly housed
and allowed to recover for at least 7 days prior to the microdialysis
experiments.
At 5 PM the day prior to the microdialysis experiments, a CMA12
microdialysis probe (polyarylethersulphone, 4-mm membrane
length, 100-kDa pore size) was inserted into the guide cannula, and
the rat was placed in a plastic shoebox cage with bedding, connected
to a two-channel swivel (Instech Solomon, Plymouth Meeting, PA),
and allowed to move freely. The probes were perfused at a constant
flow rate of 1 mL/min with a sterile artificial CSF solution (aCSF;
CNS Perfusion Fluid; CMA Microdialysis, Kista, Sweden; Harvard
Apparatus, Holliston, MA). The aCSF consisted of the following (in
mM): 148 NaCl; 4 KCl; 0.8 MgCl 2, 1.4 CaCl 2, and 1.2 Na2 HPO 4
(pH 7.2). At 8 AM the following morning, samples were collected into
a refrigerated fraction collector (Honeycomb fraction collector; Bioanalytical Systems) in 30-minute intervals for 3 hours to define the
baseline. The first two samples were discarded from analysis. For the
acute study, all animals were treated with saline upon collection of
the final baseline sample, and subsequently with either vehicle or
vortioxetine (10 mg/kg, s.c.) 1 h after completion of baseline sample
collection. Samples were then collected for 4 hours. Experiments
assessing the effects of subchronic vortioxetine on extracellular ACh
were conducted as described above, with a few modifications. After
surgery, rats were singly housed for 14 days, during which they were
given 30 g/d Purina 5001 rodent diet (vehicle), or the same amount of
food infused with 1.8 g vortioxetine per kg food. On day 15 probes were
inserted and rats were perfused with aCSF at 1.5 mL/min. After a
4-hour stabilization period, samples were collected in 20-minute
intervals for 4 hours to determine basal ACh levels. Given that the
goal in this experiment was only to compare basal ACh levels in
vehicle- and subchronic vortioxetine-treated groups, the small differences in perfusion rate and fraction collection time between the
subchronic and acute dosing experiments are not theoretically
important. After the completion of experiments, rats were anesthetized by CO2 and decapitated. Brains were quickly dissected from the
skull, flash frozen on powdered dry ice, and stored at 220°C until used
in ex vivo receptor occupancy experiments.
ACh standards were prepared in aCSF and were diluted prior to
analysis by combining 10 mL standard solution with 10 mL 1.0 ng/mL
deuterated ACh (D-ACh) solution prepared in distilled water. The
range of standards was 10–100,000 pg/mL. Microdialysis samples
were prepared in the same manner (10 mL sample and 10 mL D-ACh
stock solution) to provide 20 mL sample for analysis. Samples and
standards were prepared in plastic tubes (Bioanalytical Systems)
that were loaded into a 96-deep-well plate and then heat sealed
(Thermo Scientific Easy Peel, Waltham, MA) prior to placing them
onto the Acquity sample organizer for analysis.
A Waters Acquity high-pressure liquid chromatography system
(Milford, MA) equipped with a Sunshell RP-Aqua 2.1  100-mm,
2.6-mm particle column was used to isolate ACh prior to detection using
a Waters Quattro Premier XE triple-quadrupole mass spectrometer
operating in the mass spectrometry/mass spectrometry mode. A full
loop injection using a 5 mL loop with a 4 overfill, requiring a total
sample volume of 20 mL, was used to deliver samples onto the liquid
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Results
Social Recognition Memory Test. Vortioxetine treatment did not alter the basic drive for social interaction
observed for scopolamine. Adult rats that were administered
vehicle followed by 0.25 mg/kg scopolamine exhibited an
investigation time of 55 6 7 seconds, whereas rats administered 10 mg/kg vortioxetine followed by 0.25 mg/kg scopolamine investigated the juvenile stimulus animal for 51 6
7 seconds (t(18) 5 0.46, N.S.).
In acute administration experiments, the vehicle plus
scopolamine–treated group had significantly reduced recognition index scores compared with vehicle controls [F(5,96) 5
3.63, P , 0.01; Fig. 1A], suggesting an impairment in social
recognition memory. Post hoc tests revealed that recognition

Fig. 1. Vortioxetine effects on scopolamine-induced social recognition memory impairments. (A) Acute treatment with 0.25 mg/kg scopolamine significantly impaired social recognition memory performance. Acute vortioxetine
treatment at 0.1–3 mg/kg did not significantly reverse scopolamineinduced impairments in this task, although 10 mg/kg vortioxetine did.
(B) Acute scopolamine impaired social recognition memory performance,
but subchronic treatment with vortioxetine (1.8 g vortioxetine/kg food,
p.o. ad libitum) failed to reverse scopolamine-induced deficits. N = 12–24
rats per group. Plus signs represent significant differences in post hoc
tests from the vehicle/vehicle condition (+P , 0.05; ++P , 0.01), whereas
asterisks represent significant differences versus the vehicle/scopolamine
treatment group (***P , 0.001).

index scores for animals pretreated with 0.1–3 mg/kg vortioxetine
before scopolamine administration were not significantly different from vehicle plus scopolamine–treated subjects. However,
rats administered 10 mg/kg vortioxetine plus scopolamine had
significantly higher recognition index scores as compared with
vehicle plus scopolamine–treated rats (P , 0.001).
In subchronic administration experiments, animals fed
vehicle food for 2 weeks followed by 0.25 mg/kg scopolamine
30 minutes s.c. on the day of experiments had significantly
reduced recognition index scores versus animals fed vehicle
food ad libitum followed by vehicle injection [F(2,32) 5 3.7, P ,
0.05; Fig. 1B]. Post hoc tests demonstrated that recognition
index scores in animals fed 1.8 g/kg vortioxetine food ad
libitum followed by 0.25 mg/kg scopolamine 30 minutes s.c.
were not significantly different from those observed in vehicle
plus scopolamine animals.
Object Recognition Memory. Acute administration of
scopolamine significantly reduced object recognition scores
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of object exploration (novel 1 familiar ,5 seconds) were excluded from
the data analysis. Outliers were identified using Pierce’s criterion
(Ross, 2003) and removed. The data were subsequently analyzed by
a one-way ANOVA, followed where appropriate by Fisher’s protected
t post hoc tests.
Visual Signal Detection Task. The dependent variables were as
follows: 1) percent hits 5 (number of correct responses on signal trials/
the number of signal trials completed)  100; 2) percent correct
rejections 5 (number of correct responses on blank trials/the number
of blank trials completed)  100; 3) response latency 5 total time
elapsed from when the levers were extended to when a lever press
occurred/the number of trials completed (these data were collapsed
across signal and blank trials); and 4) response omissions 5 total
number of trials where no response occurred (these data were
collapsed across signal and blank trials). A two-factor repeated
measures ANOVA was applied with signal intensity and treatment
condition as factors for percentage of hits. The F-values reported in
text for this dependent measure relate to the treatment  stimulus
intensity interaction effects. A one-way repeated measures ANOVA
was used to assess the effect of treatment condition on percent correct
rejections, response latency, or trial omissions. A significant ANOVA
model was followed by a Fisher’s protected t post hoc test.
Drug Exposure Experiments. Scopolamine or vortioxetine
plasma concentrations are expressed as nM and mM, respectively,
whereas brain concentrations are expressed as either nmol/kg or
mmol/kg. The brain to plasma ratio was calculated by dividing the
brain concentration by plasma concentration. Data were analyzed
using independent samples t tests. In vortioxetine time course
experiments, the peak vortioxetine level was determined empirically,
and the elimination of vortioxetine from the plasma and blood was
modeled using a one-phase exponential decay regression model.
Statistical analysis of microdialysis experiments was performed, as
reported previously (Pehrson et al., 2013). For the acute dosing study,
the raw ACh concentrations were normalized to the average basal
ACh concentrations observed in the vehicle group. Subsequently,
the area under the curve for each individual animal’s normalized
extracellular ACh concentration was calculated using the trapezoid
method for fractions 4–9 (0–150 minutes on Fig. 4), which constituted
the entirety of vortioxetine’s apparent time course on extracellular
ACh concentrations. Area under the curve data from the vehicle and
vortioxetine groups were compared using unpaired two-tailed independent samples t tests. This analytical method was preferred for
its simplicity; however, similar significance values were observed
using a more traditional two-factor ANOVA of normalized extracellular ACh concentrations, including data from all dialysate fractions.
For the subchronic dosing study, the basal extracellular ACh concentration was defined for each animal by taking the average of all
dialysate fractions collected. These basal values were normalized to
the average basal concentration for the vehicle animals and compared
using a two-tailed independent samples t test.
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versus vehicle control subjects [F(5,63) 5 23.02, P , 0.001;
Fig. 2]. Recognition index scores in animals treated with
3.9 mg/kg vortioxetine were not significantly different from
those in animals in the vehicle plus scopolamine group.
However, recognition index scores for animals in the 7.9 mg/kg
vortioxetine plus scopolamine group were significantly higher
than those of animals in the vehicle plus scopolamine group.
Additionally, animals in the 0.4 mg/kg donepezil plus scopolamine and 1.3 mg/kg donepezil plus scopolamine groups had
significantly higher recognition index scores as compared with
the vehicle plus scopolamine group.
Visual Signal Detection Task. Scopolamine 0.25 mg/kg
produced a significant reduction in percent hits [F(6,84) 5 32.08,
P , 0.001; Fig. 3A] and correct rejections [F(3,42) 5 29.49, P ,
0.001; Fig. 3B] versus the vehicle plus vehicle condition.
Vortioxetine 10 mg/kg did not influence scopolamine-induced
deficits on percent hits or correct rejections. Vortioxetine by itself
did not produce any significant changes in percent hits or correct
rejections (Fig. 3, A and B). Similar effects were observed in other
VSDT-dependent measures. Scopolamine 0.25 mg/kg significantly increased response latencies [F(3,42) 5 120.20, P , 0.001;
Supplemental Table 1] and response omissions [F(3,42) 5 59.27,
P , 0.001; Supplemental Table 1] versus vehicle controls, and
vortioxetine significantly enhanced these effects. When administered alone, vortioxetine did not affect response latency or
omissions.
Scopolamine 0.1 mg/kg also produced a significant reduction
in percent hits [F(6,90) 5 30.75, P , 0.001; Fig. 3C] and correct
rejection [F(3,45) 5 22.92, P , 0.001; Fig. 3D] versus vehicle
controls. Pretreatment with 10 mg/kg vortioxetine did not
alter these scopolamine-induced deficits. Consistent with the
previous experiment, vortioxetine alone did not have any
effect (Fig. 3, C and D). As observed with the higher
scopolamine dose, 0.1 mg/kg scopolamine significantly increased the response latencies [F(3,45) 5 128.30, P , 0.001;
Supplemental Table 1] and omissions [F(3,45) 5 58.13, P ,
0.001; Supplemental Table 1] versus the vehicle plus vehicle
control group and vortioxetine enhanced these effects. Once

again, vortioxetine by itself did not produce a significant
effect.
Finally, the effects of the acetylcholinesterase inhibitor
donepezil on the deficits induced by 0.1 mg/kg scopolamine
were studied. As observed previously, 0.1 mg/kg scopolamine
significantly impaired signal detection performance by decreasing the accuracy of percent correct hits [F(6,84) 5 8.77,
P , 0.001; Fig. 3E] and rejections [F(3,42) 5 13.97,
P , 0.001; Fig. 3F] versus the vehicle control group. Pretreatment with 3 mg/kg donepezil significantly improved
scopolamine-induced deficits on percent correct hits (selectively at 2.4-lux stimulus intensity) and rejection accuracy
(Fig. 3, E and F). Donepezil had no significant effects on percent
correct hits or rejections when administered alone. As observed
in previous trials, scopolamine increased response latencies
[F(3,42) 5 16.94, P , 0.001; Supplemental Table 1] and omissions
[F(3,42) 5 3.3, P , 0.05; Supplemental Table 1] versus vehicle
controls. Donepezil had no effect by itself on these measures, but
donepezil pretreatment reversed scopolamine-induced increases
in response omissions (although scopolamine effects on omissions
were small).
Drug Exposure Studies. Scopolamine exposure levels
after 0.1 mg/kg scopolamine were unaffected by pretreatment with 10 mg/kg vortioxetine [plasma (t[14] 5 1.56, N.S.),
brain (t[14] 5 0.23, N.S.); Table 1]. The brain to plasma
ratio of scopolamine was also unchanged [t(14) 5 0.85, N.S.].
Rats treated with vortioxetine showed significantly higher
vortioxetine plasma concentrations than animals treated
with vortioxetine plus 0.1 mg/kg scopolamine [t(14) 5 2.74,
P , 0.05]. However, this did not translate into a difference
in vortioxetine brain concentrations between the two treatment groups [t(14) 5 0.13, N.S.], or in the brain to plasma ratio
[t(14) 5 1.19, N.S.].
Simple visual inspection of the time course for plasma and
brain levels after 10 mg/kg vortioxetine shows peak plasma
(2.1 6 0.13 mM) and brain (660 6 19 mmol/kg) exposure
approximately 2 hours after dosing (Fig. 4). Further analysis
of these data using nonlinear regression revealed an apparent
plasma half life of 3.9 hours (95% confidence interval: 2.8–6.5
hours), and the half life in brain was calculated to be 5.1 hours
(95% confidence interval: 3.4–10 hours).
In Vivo Microdialysis Measurement of Extracellular
ACh in the Ventral Hippocampus. In the acute dosing
experiment, the mean basal extracellular ACh concentrations
were 66 6 15 and 69 6 11 pg/mL, respectively, for the vehicleand vortioxetine-treated groups (Fig. 5). Acute vortioxetine
injections produced a relatively small, but statistically significant increase in extracellular ACh concentration versus the
vehicle group [t(12) 5 2.486, P , 0.05]. The increase was shortlived and peaked at approximately 150% of basal concentrations from 60–90 minutes postvortioxetine dose before quickly
returning to basal levels by 3 hours postdose.
In the subchronic dosing experiment, extracellular ACh
concentrations measured over a period of 3 hours were 47 6
7 and 50 6 14 pg/mL, respectively, in vehicle- and vortioxetine
(1.8 g/kg food)-treated animals (basal concentrations normalized to the average vehicle baseline were 100 6 16% and 106 6
30%, respectively; Fig. 6). These values did not differ statistically significantly [t(12) 5 0.17, N.S.].
Ex Vivo Autoradiography Experiments. Acute vortioxetine
(10 mg/kg, s.c., 1 hour) produced ∼99% SERT and 80%
5-HT 1B receptor occupancy (Table 2). Similarly, animals
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Fig. 2. Vortioxetine effects on scopolamine-induced object recognition
memory impairments. Acute treatment with 3.47 mg/kg scopolamine
significantly impaired object recognition memory performance. The 3.9 mg/kg
vortioxetine did not reverse scopolamine-induced impairments, but 7.9 mg/kg
induced a significant improvement in performance compared with scopolamine alone. Donepezil (Don) treatment at either 0.4 or 1.3 mg/kg significantly improved object recognition performance compared with scopolamine
alone. N = 9–18 rats per group. Plus signs represent significant differences
from the vehicle/vehicle treatment group, whereas asterisks represent
significant differences versus the vehicle/scopolamine group (*P , 0.05;
***P , 0.001; ****P , 0.0001).
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Fig. 3. Effects of vortioxetine and donepezil on scopolamine-induced impairments of VSDT performance. Left panels show effects of a given treatment
on scopolamine-induced deficits in percent correct hits. Right panels show effects of a given treatment on scopolamine-induced deficits in percent
correct rejections. (A and B) Acute treatment with 0.25 mg/kg scopolamine (Scop) significantly impaired VSDT performance, and these impairments
were not reversed by 10 mg/kg vortioxetine. (C and D) Acute treatment with 0.1 mg/kg scopolamine also significantly impaired VSDT performance,
and again 10 mg/kg vortioxetine did not reverse these effects. (E and F) The 0.1 mg/kg scopolamine once again significantly impaired VSDT
performance. Acute treatment with 3 mg/kg donepezil (Don) induced a small, but significant improvement compared with scopolamine alone,
which was limited to the 2.4-lux stimulus intensity. N = 15–16 rats per group. Asterisks represent significant differences from vehicle/vehicle (++P , 0.01;
+++
P , 0.001). Plus signs represent significant differences from vehicle/scopolamine (**P , 0.01).
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TABLE 1
No pharmacokinetic interactions exist between acute vortioxetine and scopolamine
Bioanalysis of plasma and brain exposure to vortioxetine and scopolamine using administration routes and times relevant for the behavioral experiments presented in this
study reveals no pharmacokinetic interactions between vortioxetine and scopolamine. Data are presented as mean 6 S.E. N = 8 rats per group.
Vortioxetine

Scopolamine

Treatment Group

Scopolamine (0.1 mg/kg, s.c., 30 minutes)
Vortioxetine (10 mg/kg, s.c., 1 hour)
Vortioxetine (10 mg/kg, s.c., 1 hour)
+ scopolamine (0.1 mg/kg, s.c., 30 minutes)
a

Plasma (mM)

Brain (mmol/kg)

Brain:Plasma

Plasma (nM)

Brain (nmol/kg)

Brain:Plasma

0
2.3 6 0.1a
1.9 6 0.08

0
34 6 2.6
34 6 2.9

0
15 6 1.1
17 6 1.4

60 6 6.2
0
74 6 7.1

330 6 60
0
340 6 60

5.7 6 1.1
0
4.6 6 0.6

Significant difference from vortioxetine + scopolamine group.

treated subchronically with vortioxetine-infused food had 99% of
SERT and 81% of 5-HT1B receptors occupied.

This is the first in-depth study to empirically evaluate the
proposed relationship between vortioxetine’s effects on cognitive function and ACh neurotransmission. We found that
acute vortioxetine reversed scopolamine-induced deficits in
social and object recognition memory-related tasks, but not in

Fig. 4. Time course of vortioxetine exposure in plasma and brain after
acute 10 mg/kg s.c. treatment. Plasma vortioxetine exposure peaked at
2 hours postdose and had an apparent half life of 3.9 hours (95%
confidence interval 2.8–6.5 hours). Brain vortioxetine exposure peaked at
2 hours postdose and had an apparent half life of 5.1 hours (95%
confidence interval 3.4–10 hours). N = 3 per group.
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Discussion

an attention-related VSDT. However, vortioxetine had no
effect on social recognition memory after subchronic administration at an equivalent dose (Table 2). In line with previous
observations in the prefrontal cortex (Mørk et al., 2013), acute
vortioxetine caused a small and transient, but significant
increase of hippocampal ACh. The transient nature of this
effect on hippocampal ACh levels cannot be explained by
vortioxetine’s kinetics, because brain exposure did not peak
until 2 hours postadministration, and the brain elimination
half life is 5.1 hours. Furthermore, subchronic vortioxetine
administration at an equivalent dose failed to alter basal
hippocampal ACh levels. Overall, these data suggest that
vortioxetine’s effects on cholinergic neurotransmission are
relatively small and short-lived, reducing the likelihood that
altered cholinergic neurotransmission is the primary mechanism mediating vortioxetine’s sustained positive effects on
cognitive function.
In line with published evidence, we observed that dysregulating cholinergic neurotransmission via administration of the
nonselective muscarinic receptor antagonist scopolamine induced significant deficits in social and object recognition memory
performance in rats (Winslow and Camacho, 1995; Lieben et al.,
2005; de Bruin and Pouzet, 2006; Millan et al., 2007; Riedel et al.,
2009; de Bruin et al., 2010). Acute vortioxetine administration
significantly reversed scopolamine-induced memory deficits in
these tasks, but only at the high end of the clinically relevant
dose range (Leiser et al., 2014), that is, a modest but significant
effect at 10 mg/kg in the social recognition memory task and
at 7.9 mg/kg in the object recognition task. Given the wellcharacterized relationship between dose and target engagement
for this drug, these data may provide some hints at the receptor
mechanisms that are relevant for vortioxetine’s ability to reverse
scopolamine-induced deficits. Vortioxetine selectively and fully
occupies 5-HT3 receptors at low doses (ED80 5 0.1 mg/kg), and
as the dose increases vortioxetine engages SERT (ED80 5
1.2 mg/kg), 5-HT1B receptors (ED80 5 9 mg/kg), and 5-HT1A
and 5-HT7 receptors (du Jardin et al., 2014; Leiser et al., 2014).
Therefore, 5-HT3 receptor antagonism and SERT inhibition
appear to be insufficient alone, and either 5-HT1B receptor
partial agonism, 5-HT1A receptor agonism, 5-HT7 receptor antagonism, or some combination thereof is necessary for vortioxetine’s
effects in these tasks. However, because 5-HT receptor-mediated
modulation of scopolamine-induced recognition memory deficits
is poorly studied, it is difficult to further evaluate our findings.
Although acute vortioxetine reversed scopolamine-induced social
recognition memory deficits, a similar effect was not observed in
animals treated subchronically with an equivalent vortioxetine
dose. The cause of this loss of efficacy is not yet understood, but
may involve desensitization of the relevant receptor effect.
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Fig. 5. Acute vortioxetine effects on extracellular acetylcholine concentrations in the ventral hippocampus. Acute 10 mg/kg vortioxetine treatment
induced a transient and relatively small, but significant increase in
hippocampal extracellular ACh compared with vehicle control animals.
Comparison of the area under the curve for vehicle- and vortioxetine-treated
animals. N = 6–8 rats per group. Asterisks represent significant differences
from the vehicle control group (*P , 0.05; **P , 0.01).

To examine whether elevation of extracellular ACh is
mechanistically relevant for reversing scopolamine-induced
object recognition memory deficits, we investigated the effects
of acute treatment with the cholinesterase inhibitor donepezil.
We found that acute donepezil (0.4 and 1.3 mg/kg) significantly attenuated scopolamine’s effects. This agrees with
published data showing that the cholinesterase inhibitors
galantamine and metrifonate reversed scopolamine’s effects
in this model (Lieben et al., 2005; de Bruin and Pouzet, 2006).
We did not test donepezil in the social recognition memory
task, but the literature has consistently shown that cholinesterase inhibition reverses scopolamine-induced deficits in this
model (Winslow and Camacho, 1995; Millan et al., 2007;
Riedel et al., 2009; de Bruin et al., 2010). Thus, it appears
that elevating extracellular ACh concentrations can consistently reverse scopolamine’s negative effects on recognition
memory, although the precise receptor mechanism is unclear.
In line with previous reports, we observed that acute
scopolamine administration significantly impairs VSDT performance (McQuail and Burk, 2006; Rezvani et al., 2009;
Freitas et al., 2015). Acute vortioxetine failed to improve
scopolamine-induced impairments of VSDT performance measures related to attention (i.e., hits and correct rejections) and
accentuated scopolamine-induced deficits in response latency
and omissions, measures that may be consistent with changes

in arousal or motivation. This is most likely a pharmacodynamic effect because coadministration of scopolamine and
vortioxetine had no impact on brain concentrations of either
drug. However, the mechanisms driving these effects on
response latency and omissions are unknown. Vortioxetine
alone consistently failed to alter performance in any of the
VSDT-dependent measures, whereas donepezil (3 mg/kg)
attenuated scopolamine-induced deficits. However, the effect
was only partial and only observed at the highest signal
intensity level. The 3 mg/kg donepezil dose is notably higher
than the dose needed to reverse scopolamine-induced deficits
in the object recognition test (0.4 mg/kg). Furthermore, a s.c.
administration of this donepezil dose is expected to produce a
marked increase in extracellular ACh. Thus, it appears that
increasing extracellular ACh levels is insufficient to fully
reverse scopolamine-induced VSDT deficits.
Vortioxetine at 10 mg/kg s.c. caused a relatively small,
transient, but statistically significant increase in extracellular
ACh in the ventral hippocampus. This observation is similar
to our previously reported small and transient extracellular
ACh increase in the prefrontal cortex (Mørk et al., 2013). Thus,
these data serve to further substantiate the presence of an
indirect effect of vortioxetine on extracellular ACh, and to
extend this effect to a new region of the brain. The precise
receptor mechanism or downstream system-level mechanism
that drives vortioxetine’s effects on extracellular ACh cannot
be empirically discerned based on these data and is outside the
intended scope of the experiments presented in this work.
However, given the vortioxetine dose-effect curve observed for
cortical extracellular ACh (Mørk et al., 2013), the responsible
receptor mechanism must be one that becomes occupied to a
biologically meaningful level between 2.5 and 10 mg/kg
vortioxetine, and is either present in cholinergic terminal
regions such as the frontal cortex and hippocampus, or in the
basal forebrain, where cholinergic fibers originate (McKinney
et al., 1983). Based on these restrictions, the receptor that is
most likely to be involved is the 5-HT1B receptor, which is on
the ascending portion of its dose-occupancy curve between 2.5
and 5 mg/kg (Leiser et al., 2014), is present at high levels in
both the medial frontal cortex and hippocampus (Dale et al.,
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Fig. 6. Subchronic vortioxetine effects on basal extracellular acetylcholine concentrations in the ventral hippocampus. Fourteen-day treatment
with vortioxetine-infused food (1.8 g vortioxetine/kg food, p.o., ad libitum)
failed to alter basal extracellular ACh concentrations compared with
vehicle controls. N = 5–7 rats per group (n.s., not significant).

Vortioxetine on Scopolamine-Induced Cognitive Impairment
TABLE 2
Estimated fractional target occupancy values at the SERT and 5-HT1B
receptor after acute or subchronic vortioxetine administration
Vortioxetine occupied the same fraction of SERT and 5-HT1B receptor targets using
acute administration at 10 mg/kg 1 hour s.c. or 14 day p.o. administration via ad
libitum feeding with rodent chow infused with 1.8 g vortioxetine/kg food weight.
Thus, these dosing regimens are considered equivalent. Data are presented as mean
6 S.E.M. N = 6 rats per group.
Estimated Target Occupancy (%)
Treatment Condition

Vortioxetine (10 mg/kg, s.c., 1 hour)
Vortioxetine (1.8 g/kg food weight
p.o. libitum, 14 days)

SERT

5-HT1B Receptor

99 6 1.4
99 6 0.7

80 6 2.9
81 6 2.6

This is consistent with vortioxetine’s inability to reverse
scopolamine-induced impairments in social recognition
memory task after subchronic administration.
There are important caveats to consider when evaluating
these data. Importantly, vortioxetine’s affinity for rat 5-HT1A
and 5-HT7 receptors is approximately an order of magnitude
lower than for the human counterparts (Sanchez et al., 2015).
Therefore, if vortioxetine’s cholinergic mechanisms are mediated via effects at either of these targets, then our study
may have underestimated the impact of the cholinergic
system in clinical populations. Additionally, the behavioral
data are limited to assessments of social recognition memory,
object recognition memory, and attention; thus, caution
should be exercised when extrapolating to other cognitive
domains that are improved by vortioxetine in the clinic, for
example, processing speed and executive function (du Jardin
et al., 2014; Jensen et al., 2014; Wallace et al., 2014; Li et al.,
2015). Moreover, although the neurochemical data presented
in this work may suggest that vortioxetine has limited effects
on cholinergic neurotransmission, this should be viewed
with caution until empirical evaluations of other cognitive
domains have been evaluated. Furthermore, whether vortioxetine
can modulate cognitive impairments induced by nicotinic, rather
than muscarinic, receptor antagonism has not been evaluated in this study. Finally, given that these studies were
conducted only in male rats, these data may not necessarily
translate into females. Therefore, further studies are needed to
evaluate vortioxetine’s effects on nicotine receptor antagonistmediated cognitive deficits, and to address whether there are sex
differences in vortioxetine’s effects on ACh neurotransmission.
In conclusion, our data suggest that vortioxetine has some
effects on memory that could be mediated through cholinergic
neurotransmission. However, the effects are only seen under
acute dosing conditions, which may argue against cholinergic
mechanisms being the primary mediator of vortioxetine’s
cognitive effects observed under chronic dosing conditions in
patients with MDD.
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